pyruvic acid has been researched along with Cognition Disorders in 8 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we evaluated protective effects of long-term administration of pyruvate in 3xTg-AD mice, a preclinical AD model that develops amyloid-β- and tau-dependent pathology." | 1.42 | Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology. ( Bomba, M; Canzoniero, LM; Ciavardelli, D; Corona, C; Curcio, M; Granzotto, A; Isopi, E; Lattanzio, R; Navarra, R; Piantelli, M; Sensi, SL, 2015) |
| "The canine counterpart of senile dementia of the Alzheimer type (ccSDAT) is considered a promising model for examining behavioral, cellular and molecular processes involved in early phases of human brain aging and Alzheimer disease (AD)." | 1.33 | Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia. ( Andrade, C; Carrasco, JL; Mahy, N; Mas, E; Mascort, J; Pugliese, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Foolad, F | 1 |
| Khodagholi, F | 1 |
| Nabavi, SM | 1 |
| Javan, M | 1 |
| Galan, A | 1 |
| Carletti, BE | 1 |
| Morgaz, J | 1 |
| Granados, MM | 1 |
| Mesa, I | 1 |
| Navarrete, R | 1 |
| Lombardo, R | 1 |
| Martínez, CM | 1 |
| Martín-Suárez, EM | 1 |
| Helbok, R | 1 |
| Schiefecker, A | 1 |
| Delazer, M | 1 |
| Beer, R | 1 |
| Bodner, T | 1 |
| Pfausler, B | 1 |
| Benke, T | 1 |
| Lackner, P | 1 |
| Fischer, M | 1 |
| Sohm, F | 1 |
| Hackl, W | 1 |
| Stover, JF | 1 |
| Thomé, C | 1 |
| Humpel, C | 1 |
| Schmutzhard, E | 1 |
| Isopi, E | 1 |
| Granzotto, A | 1 |
| Corona, C | 1 |
| Bomba, M | 1 |
| Ciavardelli, D | 1 |
| Curcio, M | 1 |
| Canzoniero, LM | 1 |
| Navarra, R | 1 |
| Lattanzio, R | 1 |
| Piantelli, M | 1 |
| Sensi, SL | 1 |
| Wang, X | 1 |
| Hu, X | 1 |
| Yang, Y | 1 |
| Takata, T | 1 |
| Sakurai, T | 1 |
| Owen, L | 1 |
| Sunram-Lea, SI | 1 |
| Suh, SW | 1 |
| Aoyama, K | 1 |
| Matsumori, Y | 1 |
| Liu, J | 1 |
| Swanson, RA | 1 |
| Pugliese, M | 1 |
| Carrasco, JL | 1 |
| Andrade, C | 1 |
| Mas, E | 1 |
| Mascort, J | 1 |
| Mahy, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of PeakATP (Adenosine 5' - Triphosphate Disodium) Supplementation vs. Placebo on Measures of Mood, Reaction Time and Cognitive Performance[NCT05100589] | 35 participants (Actual) | Interventional | 2021-10-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for pyruvic acid and Cognition Disorders
| Article | Year |
|---|---|
Metabolic agents that enhance ATP can improve cognitive functioning: a review of the evidence for glucose, oxygen, pyruvate, creatine, and L-carnitine.
Topics: Adenosine Triphosphate; Aging; Brain; Carnitine; Cognition; Cognition Disorders; Creatine; Energy Me | 2011 |
7 other studies available for pyruvic acid and Cognition Disorders
| Article | Year |
|---|---|
Changes in mitochondrial function in patients with neuromyelitis optica; correlations with motor and cognitive disabilities.
Topics: Adult; Case-Control Studies; Cognition Disorders; Cytochromes c; Electron Transport Complex I; Elect | 2020 |
Comparative study of select biochemical markers in cerebrospinal fluid of healthy dogs before and after treatment with nutraceuticals.
Topics: Animals; Biomarkers; Brain; Chlorides; Cognition Disorders; Creatinine; Dietary Supplements; Dog Dis | 2014 |
Cerebral tau is elevated after aneurysmal subarachnoid haemorrhage and associated with brain metabolic distress and poor functional and cognitive long-term outcome.
Topics: Aged; Biomarkers; Brain; Cognition Disorders; Female; Follow-Up Studies; Glutamic Acid; Humans; Intr | 2015 |
Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Animals; Calcium; Cells, Cultured; Cerebral Cortex; | 2015 |
Systemic pyruvate administration markedly reduces neuronal death and cognitive impairment in a rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Death; Cognition Disorders; Disease Models, | 2015 |
Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment.
Topics: Animals; Cell Death; Cognition Disorders; Disease Models, Animal; Hypoglycemia; Insulin; Ketoglutari | 2005 |
Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia.
Topics: Aging; Alzheimer Disease; Animals; Behavior, Animal; Biomarkers; Brain Chemistry; Cerebrospinal Flui | 2005 |